IMDELLTRA is a first-in-class immunotherapy engineered by Amgen researchers that binds to both DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing SCLC cells.

Amgen’s Imdelltra, a delta-like ligand 3 targeting Bispecific T-cell Engager (BiTE) therapy, was approved by the FDA in 2024 for pre-treated extensive-stage small cell lung cancer (ES-SCLC ...

IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen researchers to bind to both DLL3 on tumor cells and CD3 on T cells, thereby activating T cells to kill DLL3-expressing SCLC ...

IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study ...

Tarlatamab (Imdelltra) is only for patients who have exhausted all other options to treat extensive-stage small cell lung cancer. Photo by Adobe Stock/HealthDay News ...

Initiate treatment with IMDELLTRA® using the step-up dosing schedule to reduce the incidence and severity of CRS. Withhold IMDELLTRA® until CRS resolves or permanently discontinue based on severity.

Imdelltra is supplied as a powder for reconstitution and further dilution in 1mg and 10mg dosage strengths. The treatment is administered as an intravenous infusion using a step-up dosing schedule ...

Amgen's Imdelltra Shows Lower Risk of Death, Other Benefits in Phase 3 Trial Published: June 2, 2025, 8:49 a.m. ET Share Resize ...

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC Skip to main content. You have permission to edit this ...

About IMDELLTRA® (tarlatamab-dlle) IMDELLTRA is a first-in-class immunotherapy engineered by Amgen researchers that binds to both DLL3 on tumor cells and CD3 on T cells, activating T cells to ...

IMDELLTRA® (tarlatamab-dlle) Important Safety Information (USPI) WARNING: CYTOKINE RELEASE SYNDROME AND NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME ...

IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care (SOC) chemotherapy.